Search

Your search keyword '"Potenza C."' showing total 425 results

Search Constraints

Start Over You searched for: Author "Potenza C." Remove constraint Author: "Potenza C."
425 results on '"Potenza C."'

Search Results

1. Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study

2. Aesthetic Treatments in Cancer Patients

Catalog

Books, media, physical & digital resources

4. Safe Integration of Encorafenib plus Binimetinib with Stereotactic Radiosurgery for Melanoma Brain Metastases: a Case Report.

5. Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study

6. Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER–study)

7. Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study

8. Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study

9. Rapid response on facial psoriasis to bimekizumab: case series

10. Effectiveness of Ixekizumab in Elderly Patients for the Treatment of Moderate-to-Severe Psoriasis: Results From a Multicenter, Retrospective Real-Life Study in the Lazio Region

11. Epidemiology, characteristics of disease and unmet needs of patients with generalized pustular psoriasis: a large Italian Delphi consensus

12. PsoBioVax: A multicentric Italian case–control study of the immunological response to anti‐SARS‐CoV‐2 vaccine among psoriatic patients under biological therapy

13. Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice

14. Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

15. Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study

16. Real-World Apremilast Use for Treatment of Plaque Psoriasis in Italy: Patient Perspective, Characteristics, and Clinical Outcomes from the DARWIN Study

17. Mycosis fungoides: creation of a prospective, interdisciplinary and multicenter study in central Italy

18. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry

19. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study

20. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis

21. Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study

22. Adverse skin reactions to personal protective equipment during COVID-19 pandemic in Italian health care workers

23. The Dermatological Effects and Occupational Impacts of Personal Protective Equipment on a Large Sample of Healthcare Workers During the COVID-19 Pandemic

24. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

25. Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis. The LION real-life multicenter prospective observational cohort study

26. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study

27. Non‐invasive instrumental examinations of cutaneous, adnexal and mucosal manifestations after SARS‐COV‐2 infection in adult and children

28. Hidradenitis suppurativa epidemiology. From the first Italian registry in 2009 to the most recent epidemiology updates - Italian Registry Hidradenitis Suppurativa project 2

29. Ultrasonography in the pathway to an optimal standard of care of hidradenitis suppurativa: the Italian Ultrasound Working Group experience

31. Effectiveness of secukinumab in the treatment of moderate–severe hidradenitis suppurativa. Results from an italian multicentric retrospective study in a real-life setting

32. Secukinumab improves anxiety and depression in patients with moderate-to-severe psoriasis: results from the SUPREME study

33. Effect of secukinumab on perception of anxiety and depression in patients with moderate to severe psoriasis: a post hoc analysis of the SUPREME study

35. Benefit of a topic ointment as co-medication with biologic drugs for the management of moderate-severe psoriasis: a prospective, observational real-life study

36. Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy

37. The clinical spectrum of COVID-19–associated cutaneous manifestations: An Italian multicenter study of 200 adult patients

38. Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study

39. Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study

40. Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis

41. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis

42. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa; results of a prospective European cohort study.

43. Relationships between root-knot nematode resistance and plant growth in upland cotton: galling index as a criterion

44. Effectiveness of Secukinumab in the treatment of moderate–severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real‐life setting

47. Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study

48. P.209 The neuropsychological characterization of aggressive behaviour in children and adolescents with CD/ODD: preliminary results from a multicentric case-control study (MATRICS_consortium)

49. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis. results from extension phase of the SUPREME study

50. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis